These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 30559630)
1. Improvement in Cardiac Function With Enzyme Replacement Therapy in a Patient With Infantile-Onset Pompe Disease. Niyazov D; Lara DA Ochsner J; 2018; 18(4):413-416. PubMed ID: 30559630 [TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy for infantile-onset Pompe disease. Chen M; Zhang L; Quan S Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436 [TBL] [Abstract][Full Text] [Related]
3. Unusual Evolution of Hypertrophic Cardiomyopathy in Non-Compaction Myocardium in a Pompe Disease Patient. Gragnaniello V; Rizzardi C; Commone A; Gueraldi D; Maines E; Salviati L; Di Salvo G; Burlina AB J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983365 [TBL] [Abstract][Full Text] [Related]
4. Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort. Byrne BJ; Colan SD; Kishnani PS; Foster MC; Sparks SE; Gibson JB; An Haack K; Stockton DW; Peña LDM; Hahn SH; Johnson J; Tanpaiboon PX; Leslie ND; Kronn D; Hillman RE; Wang RY; Cardiol Young; 2022 Mar; 32(3):364-373. PubMed ID: 34420548 [TBL] [Abstract][Full Text] [Related]
5. Hypertrophic cardiomyopathy in pompe disease is not limited to the classic infantile-onset phenotype. Lee DH; Qiu WJ; Lee J; Chien YH; Hwu WL JIMD Rep; 2014; 17():71-5. PubMed ID: 25213570 [TBL] [Abstract][Full Text] [Related]
6. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP; Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769 [TBL] [Abstract][Full Text] [Related]
7. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation. Austin SL; Chiou A; Sun B; Case LE; Govendrageloo K; Hansen P; Kishnani PS Mol Genet Metab; 2017; 120(1-2):96-100. PubMed ID: 27692944 [TBL] [Abstract][Full Text] [Related]
8. A New Mutation Causing Severe Infantile-Onset Pompe Disease Responsive to Enzyme Replacement Therapy. Moravej H; Amirhakimi A; Showraki A; Amoozgar H; Hadipour Z; Nikfar G Iran J Med Sci; 2018 Mar; 43(2):218-222. PubMed ID: 29749992 [TBL] [Abstract][Full Text] [Related]
9. The Outcome of Infantile Onset Pompe Disease in South of Iran. Moravej H; Karamizadeh Z; Paran M Iran J Pediatr; 2016 Feb; 26(1):e4473. PubMed ID: 26848380 [TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation. But WM; Lee SH; Chan AO; Lau GT Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354 [TBL] [Abstract][Full Text] [Related]
11. [A new phenotype of infantile-onset Pompe disease]. Nascimento A; Villalobos-Pinto E Rev Neurol; 2018 Feb; 66(4):121-124. PubMed ID: 29435968 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Schoser B; Roberts M; Byrne BJ; Sitaraman S; Jiang H; Laforêt P; Toscano A; Castelli J; Díaz-Manera J; Goldman M; van der Ploeg AT; Bratkovic D; Kuchipudi S; Mozaffar T; Kishnani PS; Lancet Neurol; 2021 Dec; 20(12):1027-1037. PubMed ID: 34800400 [TBL] [Abstract][Full Text] [Related]
13. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983 [TBL] [Abstract][Full Text] [Related]
15. Resolution of severe cardiomyopathy in infantile Pompe disease. Parent JJ; Schamberger M Cardiol Young; 2015 Jan; 25(1):146-8. PubMed ID: 25544546 [TBL] [Abstract][Full Text] [Related]
17. Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa. Gragnaniello V; Fecarotta S; Pecoraro A; Tarallo A; Catzola A; Spadaro G; Parenti G; Della Casa R Neurol Sci; 2019 Jul; 40(7):1453-1455. PubMed ID: 30778879 [TBL] [Abstract][Full Text] [Related]
18. Severe Cardiomyopathy as the Isolated Presenting Feature in an Adult with Late-Onset Pompe Disease: A Case Report. Mori M; Bailey LA; Estrada J; Rehder CW; Li JS; Rogers JG; Bali DS; Buckley AF; Kishnani PS JIMD Rep; 2017; 31():79-83. PubMed ID: 27142047 [TBL] [Abstract][Full Text] [Related]
19. Occurrence of nutritional hypocalcaemic rickets-related dilated cardiomyopathy in a child with concomitant rickets and infantile-onset Pompe disease. Yeşilbaş O; Epçaçan S Cardiol Young; 2019 Mar; 29(3):425-427. PubMed ID: 30678746 [TBL] [Abstract][Full Text] [Related]
20. Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy. Avula S; Nguyen TM; Marble M; Lilje C Echocardiography; 2017 Apr; 34(4):621-624. PubMed ID: 28266734 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]